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Abstract
Background: Invasive fungal infections (IFI) remain a significant cause of morbidity and mortality in
orthotopic liver transplantation (OLT) recipients. In this retrospective study, the outcomes of a protocol
using once weekly fluconazole for 3 months after OLT in low- and high-risk patients were reviewed.
Methods: In total, 221 OLTs were evaluated in the 3-year period after institution of the new protocol to
determine the incidence of IFI within 6 months post-OLT.
Results: In this cohort, 11 IFIs developed during the 6-month post-transplant period, with the majority
being non-albicans Candida. High-risk patients had a greater rate of IFI (16.7% versus 3.4%, P = 0.038)
and a significantly longer intensive unit care (ICU) and hospital lengths of stay compared with low-risk
patients. Patient and graft survival were similar between the groups. Our patient population appeared to
be at low risk for IFI, with 92% of the entire cohort considered low risk.
Discussion: Given the low incidence of IFI in the low-risk group and the possibility of such protocol
selecting out for fluconazole-resistant fungi, the use of weekly fluconazole for 3 months may not be
justifiable in low-risk OLT recipients. Given the increased resource utilization observed with IFI, further
examination of a more intensive prophylactic strategy in high-risk patients may be warranted.
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Introduction
The incidence of invasive fungal infections (IFI) after orthotopic
liver transplant (OLT) varies in the literature from 15% to
67%.1–4 Candida and Aspergillus are the most common pathogens
and these infections predominantly occur within the first 2
months after transplantation.1 Although IFIs comprise only
20–30% of all infections post-OLT, they are associated with mor-
tality rates of 65–90% for invasive aspergillosis and 30–50% for
invasive candidiasis.1,5 In spite of the high associated morbidity
and mortality of such infections post-OLT, the optimal anti-
fungal prophylaxis regimen remains unclear. As a result there is
not a consistent centre-to-centre approach. Some centres do not
routinely administer antifungal prophylaxis to all liver transplant
recipients as a result of the uncertain clinical benefits of prophy-
laxis, cost, potential toxicity and the risk of emergence of resist-
ance.5 Other centres have adopted a targeted approach, in which
antifungal prophylaxis is provided only to those patients who
are at a high risk for IFI. According to a recent survey of North
American adult liver transplant centres, 28% practice universal
prophylaxis whereas the remaining 72% take a targeted approach
to antifungal prophylaxis.5
For centres practicing targeted prophylaxis, there is variability
regarding the criteria used to define patients who are at high risk
for IFI. Furthermore, there is not agreement on the optimal
prophylaxis regimen. The preferred agents for targeted prophy-
laxis among 67 North American adult liver transplant centres
include fluconazole in 66%, echinocandins in 21%, amphotericin
B in 11% and itraconazole in 2%.5 There are multiple known risk
factors associated with the development of IFI after liver trans-
plantation, with the most common described in Table 1.2,6–10 The
2009 Infectious Diseases Society of America (IDSA) invasive
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candidiasis guidelines utilize many of these defined risk factors to
classify a patient at high risk for the development of an IFI after
liver transplantation.11
In August 2005, a protocol was implemented at our facility in
which all OLT patients received antifungal prophylaxis with flu-
conazole 200 mg i.v./p.o. once weekly for 3 months, regardless
of the risk factors for IFI. This protocol was used in place of the
nystatin swish and swallow suspension given four times daily, each
for the prevention of oral candidiasis. The purpose of this proto-
col change was to offer an agent effective for the prevention of oral
candidiasis that was free from drug interactions and significant
toxicity, while also providing a less frequent dosing regimen at a
lower cost. Given the novelty of this fungal prophylaxis approach,
we reviewed the results of this regimen in a large cohort of liver
transplant recipients. The purpose of this study was to determine
the incidence of IFI in our cohort of patients and to determine
if the incidence varied significantly between low- and high-risk
recipients. Furthermore, we sought to determine if a once weekly
fluconazole approach for the prevention of oral thrush was
leading to a higher incidence of fluconazole-resistant fungi.
Methods
Study population
After approval from the Human Research Protection Office at
Washington University School of Medicine in St. Louis, we
reviewed 255 consecutive OLTs performed between 3 July 2005
and 3 July 2008 at our transplant centre. Clinical and demo-
graphic patient data were obtained through both inpatient and
outpatient medical records. The Organ Transplant Tracking
Record database was primarily used to obtain donor cytomegalo-
virus (CMV) status, maintenance immunosuppression regimens,
and pre- and post-transplant antibiotics or infections unavailable
through our inpatient records. All data were analysed per trans-
plant rather than per patient (with the exception of age, gender,
race and an age-modified Charlson Comorbidity Index score). For
analysis of the outcome measures, the patients were divided into
high- and low-risk cohorts based on their risk factors for invasive
fungal infections.
Inclusion criteria were age 18 years old, OLT procedure
during the study period and initiation of fluconazole 200 mg i.v./
p.o. weekly immediately post-transplant. Exclusion criteria were
death prior to the initiation of fungal prophylaxis or the use of an
antifungal regimen other than fluconazole 200 mg i.v./p.o. weekly.
Definitions
High-risk OLT was defined according to the 2009 IDSA candidia-
sis guidelines as having 2 of the risk factors for IFI:
re-transplantation, renal insufficiency defined as serum creatinine
>2 mg/dL or dialysis within 48 h prior to transplant, biliary-
enteric anastomosis, intra-operative use of > 40 units of cellular
blood products (packed red blood cells or platelets), operative
time >11 h and fungal colonization detected between 2 days
before to 3 days after transplant.11
Low-risk OLT was any transplant that did not meet the above
criteria for high-risk OLT.
Bacterial infection was classified as such if there was a positive
culture or documentation of infection in outpatient notes. Blood
cultures positive for likely contaminants unless the same organism
was isolated from 2 blood specimens taken from different sites
simultaneously or at different times, but within 7 days of the
initial collection were excluded.
CMV viremia was denoted as a positive result on CMV
polymerase chain reaction from a blood specimen.
CMV infection was based on evidence of isolation of CMV
from urine or throat washings.
CMV disease was defined as clinical evidence of organ dysfunc-
tion in addition to isolation or histological evidence of CMV from
the affected organ.
Fungal colonization was considered to be isolation of fungus
from a non-sterile site (i.e. Jackson–Pratt drain, mucosal surfaces,
stool, sputum, urine or wound).
Invasive fungal infection was defined as fungemia, positive
cryptococcal or histoplasma antigen, fungus isolated from a nor-
mally sterile site (i.e. cerebrospinal fluid, pleural fluid or perito-
neal fluid), or positive pathology for fungal elements on biopsy.
Age-modified Charlson Comorbidity Index score predicts
1-year mortality in patients with varying comorbid conditions.
The score is derived on a point system in which each comorbid
condition is assigned 1, 2, 3 or 6 points depending on the associ-
ated risk of mortality with a given comorbidity. The sum of the
points predicts the corresponding annual mortality rate: low score
(<3), 0.03; moderate score (4–5), 0.13; high score (6–7), 0.27; and
a very high score (>8), 0.49.
Outcome measures
The primary endpoint was the development of an IFI within the
first 6 months after OLT. Secondary outcomes included graft loss;
Table 1 Risk factors for the development of invasive fungal infec-
tions post-orthotopic liver transplant2,6–10
Retransplantation
Biliary-enteric anastomosis
Use of > 40 units of cellular blood products (packed red blood cells
or platelets intra-operatively)
Pre-transplant renal insufficiency (serum creatinine >2 mg/dl or
dialysis)
Operative time >11 h
Fulminant hepatic failure
Peri-operative fungal colonization
Return to operating room within 5 days for intra-abdominal bleeding
Biliary anastomotic leak
Vascular thrombosis
Post-transplant bacterial infection
Post-transplant CMV infection
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intensive care unit (ICU) and hospital length of stay (LOS); 30-,
60-day, 6- and 12-month mortality.
Statistical analysis
All nominal data were analysed with either the chi-square or Fish-
er’s exact test. The Student’s t-test was used for parametric con-
tinuous data whereas the Mann–Whitney U-test was utilized
for non-parametric continuous data. Continuous data across
more than two groups were analysed using anova. We considered
P-values less than 0.05 (two-sided) to be statistically significant.
We conducted a multivariable analysis using backward logistic
regression. All statistical analyses were performed using SPSS,
version 16.0 (SPSS Inc., Chicago, IL, USA).
Results
Patient and transplant characteristics
There were 255 OLTs performed in 246 patients during the study
period. Seven patients underwent two OLTs and one patient
received three. Thirty-four OLTs were excluded as a result of ini-
tiation of an antifungal prophylactic regimen other than flucona-
zole 200 mg i.v./p.o. weekly (n = 30) or death prior to starting
antifungal prophylaxis (n = 4). The remaining 221 OLTs (214
patients) met inclusion criteria. Eight patients underwent simul-
taneous kidney transplantations, and all met the low-risk crite-
rion. In total, 18 transplants were considered high risk and 203
were considered low risk. Figure 1 summarizes the inclusion and
exclusion criteria for this analysis. Baseline characteristics for
the 214 patients are summarized in Table 2. When patient demo-
graphics were analysed, there were no significant differences
between the high- and low-risk cohorts.
Table 3 summarizes the characteristics by transplant. Com-
pared with the low-risk cohort, the high-risk cohort had a signifi-
cantly higher model for end-stage liver disease score (25 versus 18,
P < 0.001), requirement for haemodialysis within 48 h prior to
transplant (11.1% versus 1%,P = 0.034) and were more frequently
retransplantations (77.8% versus 1%, P < 0.001). The most
common indication for OLT in the low-risk group was end-stage
liver disease secondary to Hepatitis C cirrhosis (34.5%) and graft
failure (55.6%) in the high-risk group. There were significantly
more patients in the high-risk group that had graft failure and
graft thrombosis as primary indications for OLT, whereas biliary
reasons for transplant were significantly more common in the
low-risk group, compared with the high-risk group. No difference
was found between the two groups regarding the use of antibiotics
for 72 h, bacterial infection or CMV viremia within the month
255 liver transplants during the study period
(246 patients) 
34 OLT excluded
221 remaining OLT
(214 patients) 
18 high-risk
OLT 
203 low-risk
OLT
4 for death
prior to initiation
of antifungal
30 for non-
study antifungal
prophylaxis
regimen
Data Available for 27 OLT
о 15 – fluconazole 100 mg daily 
o 6 – Nystatin S&S 
o 3 – fluconazole 200 mg daily 
o 2 – itraconazole 200 mg daily 
o 1 – voriconazole 200 mg twice daily 
Figure 1 Patient and transplant flow throughout the study
Table 2 Baseline demographics for the 214 unique patients
Characteristic HR OLT
Patients
(N = 12)
LR OLT
Patients
(N = 202)
P-value
Age, years (mean  SD) 51.8  11.8 53.5  9.1 0.13
Male, n (%) 8 (66.7%) 133 (65.8%) 1.0
Race, n (%) 0.349
Caucasian 12 (100%) 158 (78.2%)
African American 0 27 (13.4%)
Other 0 17 (8.4%)
Age-modified Charlson
Comorbidity Index
score, median (range)
5.5 (0–9) 5.0 (0–14) 0.796
HR, high risk; OLT, orthotopic liver transplant; LR, low risk.
HPB 543
HPB 2013, 15, 541–547 © 2012 International Hepato-Pancreato-Biliary Association
prior to transplant. Documented infections in the donors and
fungal colonization of the recipients did not differ significantly
between the low- and high-risk groups.
Table 4 summarized the intra- and post-operative characteris-
tics of the high- and low-risk transplants. There was no difference
in the operating time between the two groups. Transplants in
the high-risk groups were significantly more likely to include a
biliary-enteric anastamosis (94.4% versus 13.8%, P < 0.001) and
received significantly more cellular blood products intra-
operatively (9.5 versus 5 units, P = 0.01) than transplants in the
low-risk group. Post-operatively, the rate of total parenteral nutri-
tion (TPN) usage did not differ between the groups; however, the
high-risk cohort had a significantly longer median duration of
TPN use compared with the low-risk group (median 27.5 versus 6
days, P = 0.034). There was no significant difference in the rates of
re-operation for bleeding, anastomotic leak or vascular complica-
tions between the low- and high-risk groups. The incidence of
biopsy-proven acute rejection within 12 months post-transplant
did not differ between the two groups.
Immunosuppression, infection prophylaxis and
non-fungal infections
Ninety percent of patients in both groups received a tacrolimus–
mycophenolate-based immunosuppression regimen. Only those
patients who underwent a combined kidney–liver transplant
received induction immunosuppression with either thymoglobu-
lin or basiliximab. All patients received methylprednisolone (1 g
i.v.) during the anhepatic phase. Post-operatively, steroids were
tapered to maintenance (20 mg) prednisone within 5 days. All
patients were weaned completely off steroid therapy within 6
months except patients also receiving a kidney transplant who
were weaned to 5 mg daily.
No significant difference was found between the groups with
regard to infection prophylaxis. Ninety-seven per cent of the
Table 3 Characteristics for the 221 OLTs included in the analysis
Characteristic HR OLT (N = 18) LR OLT (N = 203) P-value
Admission BMI, mean  SD 26.9  6 28.7  5.3 0.191
Pre-transplant LOS, days (median, range) 1 (0–28) 0 (0–29) 0.054
Pre-transplant serum creatinine, mg/dl (median, range) 1.5 (1.0–5.3) 1.0 (1.0–8.9) 0.214
Dialysis 48 h pre-operativea 2 (11.1%) 2 (1.0%) 0.034
Mean calculated Model for End-Stage Liver Disease score 25.4  6.7 18.3  6.3 <0.001
Retransplantationa 14 (77.8%) 2 (1.0%) <0.001
Primary Indication for transplanta
Fulminant hepatic failure 0 5 (2.5%) 1.0
Hepatitis C cirrhosis 2 (11.1%) 70 (34.5%) 0.063
Hepatitis B cirrhosis 0 15 (7.4%) 0.618
Alcoholic cirrhosis 1 (5.6%) 7 (3.4%) 0.499
NASH 0 11 (5.4%) 0.606
Cryptogenic cirrhosis 2 (11.1%) 28 (13.8%) 1.0
Drug-induced hepatotoxicity 0 3 (1.5%) 1.0
Biliary 0 41 (20.2%) 0.029
Polycystic liver disease 0 3 (1.5%) 1.0
Autoimmune hepatitis 0 8 (3.9%) 1.0
Graft thrombosis 3 (16.7%) 2 (1%) 0.004
Graft failure 10 (55.6%) 3 (1.5%) <0.001
Otherb 0 7 (3.4%) 1.0
Broad-spectrum antibiotics 72 hac 5 (27.8%) 29 (14.3%) 0.165
Bacterial infectionac 1 (5.6%) 16 (7.9%) 1.0
CMV donor +/recipient -a 3 (16.7%) 13 (16.3%) 0.488
CMV viremiaac 0 1 (0.5%) 1.0
Peri-operative fungal colonizationa 1 (5.6%) 4 (2%) 0.349
aReported as n (%).
bOther indications include: granulomatous hepatitis, Budd–Chiari syndrome, Wilson's disease, sickle cell disease, amyloidosis, haemorrhagic
telangiectasia, and gastric antral vascular ectasia.
cOccurred within the 1-month period prior to transplant.
OLT, orthotopic liver transplant; HR, high risk; LR, low risk; BMI, body mass index; LOS, length of stay; NASH, nonalcoholic steatohepatitis; CMV,
cytomegalovirus.
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patients received trimethoprim–sulfamethoxazole for Pneumo-
cystis jiroveci pneumonia prophylaxis. Prophylaxis for CMV infec-
tion with valganciclovir was provided in 49 patients (24%) in
the low-risk group and 7 patients (39%) in the high-risk group
(P = 0.169). All other patients received acyclovir as antiviral
prophylaxis.
The number of infectious episodes requiring the use of broad-
spectrum antibiotics for 72 h during the first 6 months post-
OLT was not different between the groups; however, the incidence
of bacterial infection within 6 months after transplant was signifi-
cantly greater in the high-risk group (Table 4). The incidence of
CMV viremia, CMV infection and CMV disease was not signifi-
cantly different between the high- and low-risk transplants.
Invasive fungal infections
There were 11 IFIs in 10 OLTs which occurred within the initial 6
months after OLT (Table 5). Three IFIs occurred after high-risk
transplants and seven occurred after low-risk transplants. After
one low-risk transplant, the patient developed two IFIs by defini-
tion; however, these infections were caused by the same organism,
occurring at different sites within 1 week of each other. Trans-
plants in the high-risk group were significantly more likely to
develop an IFI compared with the low-risk group (16.7% versus
3.4%, P = 0.038). The majority of the IFIs were caused by Candida
species, predominantly non-albicans, and most occurred within
the first 1–2 months post-transplant. Susceptibilities were not
routinely obtained, with only two IFIs having susceptibility infor-
mation. Two of the Candida glabrata infections (IFI nos 5 and 6 in
Table 5) exhibited a dose-dependent susceptibility to fluconazole,
which is common for most C. glabrata infections.
Table 6 summarizes the results for the secondary outcomes.
There was no significant difference in graft or patient survival
between the high- and low-risk groups. Post-transplant ICU
Table 5 Invasive fungal infection by risk, date of isolation, organism
and source
IFI # Risk
of IFI
Date of
Isolation
Organism Source
1 High POD 22 C. krusei Peritoneal fluid
2 High POD 43 C. glabrata Peritoneal fluid
3 High POD 23 C. parapsilosis Blood
4 Low POD 11 C. glabrata
Zygosaccharomyces
bailii
Peritoneal fluid
5 Low POD 37 C. glabrata Peritoneal fluid
6 Low POD 43 C. glabrata Blood
7 Low POD 10,
14, 17
Cryptococcus
neoformans
Blood
8 Low POD 26 C. albicans Peritoneal fluid
9 Low POD 168 Histoplasma
capsulatum
Blood
10 Low POD 146 Candida
pseudohyphae
Esophageal
biopsy
11 Low POD 103 Scedosporium
apiospermum
Auditory canal
biopsy
IFI, invasive fungal infection; POD, post-operative day.
Table 4 Intra-operative and post-transplant characteristics for the 221 OLTs included in the analysis
Characteristic HR OLT (N = 18) LR OLT (N = 203) P-value
Intra-operative
Operative time, hours (mean  SD) 6.7  2.2 6.5  1.5 0.594
Biliary-enteric anastomosisa 17 (94.4%) 28 (13.8%) 1.0
Intra-operative transfusiona 15 (83.3%) 151 (74.4%) 0.572
Cellular blood products, units (median, range) 9.5 (1–34) 5 (0–42) 0.01
Post-Transplant
Re-operation 5 days post- transplantab 3 (16.7%) 21 (10.3%) 0.423
TPN required > 24 ha 3 (16.7%) 10 (4.9%) 0.077
TPN duration, days (median, range) 27.5 (18–37) 6 (2–51) 0.034
Dialysis 72 h post-transplanta 1 (11.1%) 5 (2.5%) 0.403
Broad-spectrum antibiotics 72 ha 10 (55.6%) 80 (39.4%) 0.214
Bacterial infectionac 10 (55.6%) 55 (27.1%) 0.016
CMV viremiaac 1 (5.6%) 24 (11.8%) 0.701
CMV infectionac 0 1 (0.5%) 1.0
CMV diseaseac 0 2 (1%) 1.0
1-year Biopsy-proven acute rejectiona 2 (11.1%) 36 (20.2%) 0.745
aReported as n (%).
bRe-operation for bleeding, anastomotic leak or vascular insufficiency.
cOccurred within the 6-month period after transplant.
OLT, orthotopic liver transplant; HR, high risk; LR, low risk; TPN, total parenteral nutrition; CMV, cytomegalovirus.
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length of stay (LOS) was significantly longer in the high-risk
group compared with the low-risk group with a median of 2.7
days (range 1–33) versus 1.8 (range 1–32) (P = 0.029). This was
also true for overall median hospital LOS of 14.9 (6–68) days
versus 7.8 (3–114) days (P = 0.002), respectively.
The multivariable analysis of all evaluated OLTs included the
following variables: Hepatitis C, alcohol or biliary cirrhosis as a
reason for transplant; retransplantation; biliary-enteric anas-
tomosis; re-operation within 5 days; re-operation for biliary
anastomotic leak; operation time; TPN duration; ICU LOS; post-
operative antibiotics 72 h; bacterial infection during the first 6
months after transplant; and low-risk grouping. This analysis
indicated that classification as low risk was the only independent
variable that was significantly associated with a reduction in the
development of IFI (odds ratio = 0.014; 95% confidence interval
0.0001–0.705).
Discussion
Invasive fungal infections continue to be a major concern after
liver transplantation. Established IFIs not only carry significant
morbidity and mortality in immunosuppressed patients, there is a
considerable economic burden associated with IFIs.1,5,12–14 One
recent study conducted in transplant recipients demonstrated that
patients that developed an IFI post-transplant resulted in $55 400
in excess costs compared with patients without an IFI.14 There are
defined risk factors for the development of an IFI after OLT which
have been validated prospectively.6 Using these criteria, we dem-
onstrated greater than a four-fold increased risk of IFI within the
first 6 months after transplant in patients classified as being at
high risk for IFI. While there was no observed increased allograft
loss or mortality in our high risk group, it is difficult to draw a
conclusion relating to mortality owing to the small high risk
cohort size. However, there was a significant increase in resource
utilization in these patients as indicated by the longer ICU and
hospital LOS. The risks for IFI development are similar to other
known risk factors for increased LOS and thus it is difficult to
determine what exact role the IFIs played in resource utilization.
However, developing an antifungal prophylaxis regimen that is
both clinically and cost-effective for all liver transplant recipients
is an important component of quality and outcome improvement.
Our patient population appears to be at low risk for IFI overall,
as 92% of our study population was considered low risk. For this
group of patients, this study shows that fluconazole 200 mg i.v./
p.o. weekly results in an IFI rate of 3.4%. This rate of IFI is similar
to the 4% rate in a recent report of non-systemic antifungal
prophylaxis with nystatin 500 000 units 4 times daily for 60 days.6
While the use of once-weekly fluconazole provides a benefit of
reduced expense, less toxicity than daily fluconazole, no clinically
significant drug interactions and a potential for increased compli-
ance and patient satisfaction over the four times daily dosing of
non-absorbable agents, the possibility of this regimen selecting
out for non-albicans Candida and non-Candida species cannot be
ignored.
Historical reports of IFI in untreated high-risk patients range
from 15% to 67%.1–4 The HR cohort in our study had a 16.7%
incidence. This rate of IFI is also similar to a report by Reed et al.
of high-risk patients who received no prophylaxis.5 The demo-
graphics were similar between the high-risk transplants in the
Reed study and those reported here with the exceptions that our
high-risk patients were more likely to be undergoing retransplan-
tation (77.8% versus 8.05%) and were less likely to return to the
operating room (16.7% versus 59.8%). Reed et al. were able to
reduce the IFI rate in high risk-patients by four-fold using a 5-day
prophylaxis regimen of amphotericin B.7 Another study examin-
ing amphotericin B did not show the same rate of decrease in IFI
after OLT in high-risk patients. Hadley et al. evaluated the safety
and efficacy of liposomal amphotericin B 2 mg/kg i.v. daily and
fluconazole 400 mg i.v. daily for 14 days in patients undergoing
OLT who were at a high risk for IFI.15 The rates for development
of IFI were equivalent between the two agents (18% with L-amB
versus 13% with fluconazole) and similar to the present results
using weekly fluconazole. The Hadley study did not include an
untreated arm and the absolute efficacy of either regimen remains
unclear.
The organisms most frequently responsible for an IFI in this
study were non-albicans Candida. It is possible this may have been
the result of our selecting out fungal organisms that were less
susceptible to fluconazole owing to the choice and dosing of anti-
fungal for prophylaxis. Of the 30 patients that did not receive
weekly fluconazole prophylaxis, only six received non-azole fungal
prophylaxis. All six of these patients were considered low risk and
none experienced an IFI. Of the other 21 patients in which there
was full data, one patient developed an IFI while on fluconazole
200 mg daily and was considered low risk. Given the lack of a
placebo control group and the small number of patients receiving
non-azole prophylaxis, it is not possible to fully elucidate whether
weekly fluconazole decreased rates of IFI, selected out for resistant
yeast, or both. The majority of IFIs after OLT occurred within the
first 2 months which is consistent with the findings of others.1,6,15
Table 6 Incidence of graft loss and death for the 221 OLTs included
in the analysis
HR OLT
(N = 18)
LR OLT
(N = 203)
P-value
Graft loss 4 (22.2) 23 (11.3) 0.248
Graft loss as a result of death 4 (22.2) 15 (7.4) 0.055
Graft loss as a result of loss of
function
0 8 (3.9) 1.0
Mortality 4 (22.2) 15 (7.4) 0.055
30-day mortality 1 (5.6) 6 (3.0) 0.453
60-day mortality 1 (5.6) 0 0.081
6-month mortality 1 (5.6) 5 (2.5) 0.403
12-month mortality 1 (5.9) 4 (2.3) 0.349
OLT, orthotopic liver transplant; HR, high risk; LR, low risk.
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Our multivariable analysis of all evaluated OLTs in this study
indicated that classification as low risk was the only independent
variable that was significantly associated with a reduction in the
development of IFI. It may be possible that certain individual risk
factors carry less impact on the development of IFI, but this study
was not able to analyze that potential.
The limitations of the study are recognized i.e. being single-
centred and retrospective in nature; however, these data have
several clinical implications. While firm conclusions cannot be
made regarding the utility of this strategy for high risk OLTs, we
believe our overall incidence of IFIs can be further reduced. The
incidence of IFI in this high-risk group was similar to the histori-
cally reported rates in high-risk patients receiving more intensive
regimens of fluconazole or L-amB.6,7,15 However, there was no
decrease in the rate of IFI in our high-risk cohort compared with
a more recent report of untreated high-risk patients.5 While
further studies are required to determine the optimal prophylaxis
strategy for decreasing the rate of IFI in high-risk OLTs, the
present findings support the use of the 2009 IDSA invasive can-
didiasis guidelines for defining patients at high risk for developing
IFI after OLT and the recommended prophylaxis strategy set forth
by this group may lead to a reduction in our IFI rate in this
population. The findings of fluconazole-resistant fungi, coupled
with the low rates of IFI in patients deemed low risk for IFIs,
suggests that the use of weekly fluconazole for the prevention of
oral candidiasis in low-risk patients may not be warranted.
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